Saturday 17 October 2026
Export CGON’s income statement to Excel — free account
CG Oncology, Inc.
CGON Healthcare Biotechnology
CG Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $4.0 million, up 254.7% from fiscal 2024. In the quarter to June 2026, revenue grew 2,125.0%, EPS fell 66.7% and free cash flow fell 67.6%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
59.79
2.07
−3.35%
Follow CGON
| Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|
Piotroski F-Score |
— | — | 5 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
— | — | 50.47 | 49.04 |
P/S ratio |
0.00 | 0.00 | 1,573.67 | 713.89 |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
2.09 | 1.52 | 40.36 | 23.13 |
Beneish M-Score |
— | (0.08) | 1.90 | — |
P/Operating CF |
(10.99) | (10.99) | (86.75) | (88.62) |
P/B ratio |
0.00 | 0.00 | 2.44 | 4.26 |
Price to Tangible BV |
0.00 | 0.00 | 2.44 | 4.33 |
EV/Sales |
0.00 | 0.00 | 935.83 | 551.48 |
EV/EBITDA |
0.19 | 0.19 | 0.00 | 0.00 |
EV/Operating CF |
0.25 | 0.25 | (13.54) | (18.73) |
EV/FCF |
0.25 | 0.25 | (13.50) | (18.72) |
Quick Ratio |
9.32 | 13.17 | 34.76 | 24.09 |
Current Ratio |
9.54 | 13.62 | 35.30 | 24.63 |
Net Debt/EBITDA |
3.64 | 3.22 | 6.20 | 3.88 |
Debt/Assets |
10.49% | 0.00% | 0.00% | 0.38% |
Debt/Equity |
(0.20) | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.01 |
Operating CF/Net income |
0.68 | 0.67 | 0.89 | 0.82 |
Capex/Depreciation |
(0.24) | 0.00 | 0.05 | (0.31) |
| 0.00% | 67.53% | (28.85%) | (21.67%) | |
| 0.00% | (39.07%) | (18.45%) | (20.82%) | |
ROIC |
0.00% | 0.00% | 0.00% | (886.69%) |
Return on Tangible Assets |
(33.21%) | (37.68%) | (12.01%) | (21.63%) |
Average Days of Receivables |
579.03 | 164.61 | 250.28 | 62.16 |
Research and Development Expense of Revenue |
15,198.43% | 22,427.45% | 7,208.25% | 2,887.15% |
Selling, General and Administrative Expense of Revenue |
3,354.97% | 4,853.43% | 2,959.00% | 1,819.95% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.01 |
Share Based Compensation of Revenue |
353.93% | 749.02% | 1,001.05% | 660.30% |
Graham Net Nets |
(0.80) | (0.80) | 0.41 | 0.22 |
Graham Number |
0.00 | 84.72 | 0.00 | 0.00 |
Earnings Yield |
(30.19%) | (30.19%) | (4.95%) | (4.99%) |
Free Cash Flow Yield |
(28.38%) | (28.38%) | (4.40%) | (4.13%) |
Revenue per Share |
0.05 | 0.05 | 0.02 | 0.05 |
Operating CF per Share |
(7.97) | (10.55) | (1.26) | (1.71) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
(7.97) | (10.55) | (1.26) | (1.71) |
Cash per Share |
38.35 | 43.33 | 11.87 | 9.60 |
Shareholders Equity per Share |
(20.77) | (28.42) | 11.73 | 9.74 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(20.77) | (28.42) | 11.73 | 9.74 |
Free Cash Flow |
(29.82) | (45.68) | (78.95) | (132.48) |
Working Capital |
131.78 | 179.87 | 732.84 | 728.64 |
Capital Expenditures |
(0.01) | — | (0.23) | (0.13) |
Net Current Asset Value |
(78.23) | (128.28) | 732.79 | 720.49 |
EV/EBIT |
0.20 | 0.20 | 0.00 | 0.00 |
Capex to Sales |
0.07 | 0.00 | 0.21 | 0.03 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||
Depreciation/Fixed assets |
0.69 | (40.84) | (18.24) | 0.03 |
Cash ROIC |
(36.68%) | (70.74%) | (5.35%) | (8.85%) |
Accounts Receivable Turnover |
0.00 | 1.03 | 2.61 | 5.50 |
Accounts Payable Turnover |
— | 0.00 | 0.00 | 0.76 |
Inventory Turnover |
— | — | — | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 448.81 |
Days of Inventory on Hand |
— | — | — | 122.92 |
Average Receivables |
— | 0.20 | 0.44 | 0.73 |
Average Payables |
— | 2.11 | 4.88 | 6.12 |
Average Assets |
— | 173.52 | 477.05 | 773.19 |
Average Common Equity |
— | (100.40) | 305.14 | 742.99 |
Columns are period end dates